Condition

Pulmonary Sarcoidosis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions2

Lead sponsors shown2

Clinical trials

3 shown

Role of Genetic Factors in the Development of Lung DiseaseNCT00001532 · 1996-09-13

RECRUITING

Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary SarcoidosisNCT03755245 · 2018-11-23

ENROLLING_BY_INVITATION

Treatment of Pulmonary Sarcoidosis With PentoxifyllineNCT00001877 · 1999-02-01

COMPLETED

Common interventions

[68Ga]Ga-DOTA-Siglec-9OTHER1 PentoxifyllineDRUG1

Leading sponsors

National Heart, Lung, and Blood Institute (NHLBI) 2 Turku University Hospital 1

Trial status mix

COMPLETED1

ENROLLING_BY_INVITATION1

RECRUITING1

Phase mix

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.